A week in tech

A summary of all the major tech stories in Asia this week broken down by country and sector.

A week in Japanese tech

Life Sciences

- Eli Lilly is to market new osteoporosis drug for Japan. Eli Lilly Japan has applied to the Health Ministry for permission to market raloxifene HCl for the treatment of osteoporosis in post-menopausal women. Eli Lilly is developing the Japanese market to compensate for the loss in revenues associated with the expiration of its patent on Prozac.

- Takeda Chemical Industries is to overhaul drug RD processes. The top-ranked pharmaceutical manufacturer will establish a new RD centre to consolidate domestic operations, and strengthen its system for coordinating clinical tests conducted in Japan, the U.S. and Europe, according to product.

- Yakult will sell Aventis Pharma adrenal...

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222